The United States Food and Drug Administration (USFDA) had conducted a pre-approval inspection (PAI) at the Moraiya facility from 23 January 2023 to 27 January 2023.

The company said that the inspection which was a PAI for transdermal patch products had concluded with nil observations.

Zydus Lifesciences is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

The company's consolidated net profit jumped 24.5% to Rs 622.90 crore on 17.9% rise in net sales to Rs 4,159.80 crore in Q3 FY23 over Q3 FY22.

Shares of Zydus Lifesciences declined 0.95% to Rs 520.35 on the BSE.